Hatzifoti Caterina, Roussel Yvonne, Harris Andrew G, Wren Brendan W, Morrow John W, Bajaj-Elliott Mona
Department of Immunology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK.
Helicobacter. 2006 Apr;11(2):113-22. doi: 10.1111/j.1523-5378.2006.00385.x.
Helicobacter pylori is recognized as a major risk factor for recurrent gastroduodenal inflammatory diseases and gastric adenocarcinoma. The high prevalence of H. pylori infection worldwide, the risks of side-effects from antibiotic therapy, and increasing resistance to antibiotics are the main primers for the development of improved H. pylori vaccines. The antigenic potential of its urease enzyme, a critical virulence factor required for colonization of the gastric mucosa, has been demonstrated in animal and human studies. An important but controversial issue in H. pylori vaccine studies is the type of immune response required to control infection. A new approach in H. pylori vaccinology is the administration of DNA vaccines, which has included heat-shock protein and catalase DNA vaccines.
The H. pylori urease subunit B construct or vector alone was administered to mice via the intranasal route. Spleens and stomachs were examined on day 0 and weeks 3, 6, and 12 after immunization. Proliferation of spleen cells was assessed using the carboxyfluorescein diacetate succinimidyl ester-based flow cytometry assay and cytokine secretion from cultured spleen cells was detected by ELISA, after stimulation with the urease subunit B recombinant antigen. Total RNA was isolated from stomach and spleen tissue and the expression of beta-defensin and cytokine genes was monitored by reverse transcription followed by polymerase chain reaction (RT-PCR). Immunized mice were challenged with H. pylori and bacterial DNA quantified by TaqMan PCR.
The urease B subunit DNA vaccine increased INF-gamma secretion and splenocyte proliferation without inducing adverse effects in the spleen. Increase in gastric beta-defensin 1 and marked induction in local IL-10 : IFN-gamma ratio up to 12 weeks post-immunization suggest a potential role for local innate immune responses in protection at the site of infection. Although significant bacterial reduction in the stomachs of urease B subunit DNA-immunized mice was observed, intermediate reduction was also noted in the vector group. Increased defensin expression and adjuvant effects of the cytosine preceding guanosine motifs may contribute to this phenomenon. Our data confirm that cytosine preceding guanosine motifs, even without coadministration with antigen, can reduce extracellular bacterial load.
In this study, a DNA construct encoding the urease B subunit was assessed for its immune profile and its ability to reduce bacterial colonization in the murine stomach. Our studies suggest that local innate immune responses may play a greater role than previously supposed in limiting H. pylori colonization in the gastric mucosa.
幽门螺杆菌被认为是复发性胃十二指肠炎症性疾病和胃腺癌的主要危险因素。全球幽门螺杆菌感染率高、抗生素治疗的副作用风险以及对抗生素耐药性的增加是研发改良型幽门螺杆菌疫苗的主要诱因。其脲酶的抗原潜力,即胃黏膜定植所需的关键毒力因子,已在动物和人体研究中得到证实。幽门螺杆菌疫苗研究中的一个重要但有争议的问题是控制感染所需的免疫反应类型。幽门螺杆菌疫苗学的一种新方法是给予DNA疫苗,其中包括热休克蛋白和过氧化氢酶DNA疫苗。
将幽门螺杆菌脲酶B亚基构建体或单独的载体经鼻内途径给予小鼠。在免疫后第0天以及第3、6和12周检查脾脏和胃。使用基于羧基荧光素二乙酸琥珀酰亚胺酯的流式细胞术检测法评估脾细胞增殖,并在脲酶B亚基重组抗原刺激后通过ELISA检测培养的脾细胞的细胞因子分泌。从胃和脾组织中分离总RNA,并通过逆转录随后进行聚合酶链反应(RT-PCR)监测β-防御素和细胞因子基因的表达。用幽门螺杆菌攻击免疫小鼠,并通过TaqMan PCR对细菌DNA进行定量。
脲酶B亚基DNA疫苗增加了INF-γ分泌和脾细胞增殖,且未在脾脏中诱导不良反应。胃β-防御素1增加以及免疫后长达12周局部IL-10:INF-γ比值显著升高,表明局部固有免疫反应在感染部位的保护中可能发挥潜在作用。虽然在脲酶B亚基DNA免疫小鼠的胃中观察到细菌显著减少,但在载体组中也注意到中度减少。鸟苷前的胞嘧啶基序增加的防御素表达和佐剂作用可能导致了这一现象。我们的数据证实,即使不与抗原共同给药,鸟苷前的胞嘧啶基序也可以减少细胞外细菌载量。
在本研究中,评估了编码脲酶B亚基的DNA构建体的免疫谱及其减少小鼠胃中细菌定植的能力。我们的研究表明,局部固有免疫反应在限制幽门螺杆菌在胃黏膜定植中可能比以前认为的发挥更大的作用。